more

Masimo (MASI)

(Delayed Data from NSDQ)

$114.27 USD

-0.78 (-0.68%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

Top 29% (77 out of 251)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medical Products' Oct 30 Earnings Roster: MCK, MASI & More

by Zacks Equity Research Published on October 29,2019

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.

Masimo (MASI) Reports Next Week: What You Should Expect

by Zacks Equity Research Published on October 23,2019

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MASINegative Net Change

Here's Why You Should Retain HMS Holdings (HMSY) Stock For Now

by Zacks Equity Research Published on September 30,2019

HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services as well as robust margins despite intense competition.

medical

Cerner (CERN) Set to Improve Patient Experience With New Deal

by Zacks Equity Research Published on September 25,2019

The collaboration with GetWellNetwork is likely to allow Cerner (CERN) in enhancing functionality for clients and patients through third-party solutions.

medical

Here's Why You Should Hold Onto Cerner (CERN) Stock for Now

by Zacks Equity Research Published on September 25,2019

Cerner (CERN) keeps its 2019 revenue guidance intact; expects improvement in bookings.

medical

NextGen's (NXGN) Population Health Picked by Ohio-Based UH

by Zacks Equity Research Published on September 24,2019

NextGen's (NXGN) EHR services are expected to enhance patient outcomes at UH.

medical

Fresenius Medical Launches 4008A Dialysis Machine in China

by Zacks Equity Research Published on September 20,2019

Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.

medical

Sleep Apnea Market Gains Momentum: 3 Stocks in Focus

by Trina Mukherjee Published on September 20,2019

Sleep apnea - a significant health issue in the United States - is a booming market, thereby reflecting promising investment prospects.

medical

Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on September 20,2019

Is (MASI) Outperforming Other Medical Stocks This Year?

MASINegative Net Change

Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome

by Zacks Equity Research Published on September 18,2019

Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.

medical

Varian's ProBeam Now Available in Multi-Room Configuration

by Zacks Equity Research Published on September 17,2019

Shandong Cancer Hospital in China selects Varian (VAR) to equip its new research center with the ProBeam Proton Therapy system.

medical

Varian's AI-Driven Ethos Solution to Boost Global Cancer Care

by Zacks Equity Research Published on September 16,2019

Varian (VAR) expects the Ethos launch to boost its Oncology Systems segment.

medical

Medidata (MDSO) Collaborates With Mapi Research to Boost Rave

by Zacks Equity Research Published on September 13,2019

Medidata's (MDSO) latest collaboration is expected to solve major eCOA implementation struggles in the pharmaceutical industry.

medical

Ecolab's (ECL) Nalco Water Opens Customer Experience Center

by Zacks Equity Research Published on September 12,2019

Ecolab (ECL) expects Nalco's water technologies to reduce freshwater usage by 20%.

medical

Masimo (MASI) Boosts O3 Platform With Three New Indices

by Zacks Equity Research Published on September 10,2019

Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.

medical

Here's Why Investors Should Retain Accuray (ARAY) Stock Now

by Zacks Equity Research Published on September 09,2019

Accuray (ARAY) slashes fiscal 2020 revenue guidance owing to tariffs in China.

medical

Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring

by Zacks Equity Research Published on September 05,2019

Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.